• Explore /
  • Poster
  • / Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

Abstract Poster

Authors

null

Josep M Llovet

Icahn School of Medicine at Mount Sinai, New York, NY

Josep M Llovet , Masatoshi Kudo , Ann-Lii Cheng , Richard S. Finn , Peter R. Galle , Shuichi Kaneko , Tim Meyer , Shukui Qin , Corina E. Dutcus , Erluo Chen , Leonid Dubrovsky , Andrew X. Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03713593

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4152)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4152

Abstract #

TPS4152

Poster Bd #

251b

Abstract Disclosures

Similar Posters

First Author: Richard S. Finn

First Author: David Trueman

First Author: Bruno Sangro

First Author: Lorenza Rimassa